HelioLiver LDT now available to order through Quest Diagnostics
HelioLiver webinar title slide featuring Dr. Robert Gish
Blog & Interviews

Hepatocellular Carcinoma (HCC): Challenges to Surveillance & Opportunities for Early Detection

Webinar 2022 2 min read Robert G. Gish, MD
Share

Dr. Robert G. Gish, Professor of Medicine at Loma Linda University, educates on hepatocellular carcinoma (HCC), early detection, surveillance challenges, and how the HelioLiver test works.

In this webinar, Dr. Gish covers:

  1. The clinical landscape of hepatocellular carcinoma (HCC)
  2. The importance of early detection and its benefits
  3. Challenges in HCC surveillance and the sub-optimal performance of current surveillance methods
  4. How HelioLiver works as a patient-friendly, simple blood test for the early detection of HCC

Watch the webinar →

View source version on youtube.com.

Related Articles

More from Helio Genomics

PublicationMay 6, 2026

CLiMB Study Published in the Journal of Hepatology

Our landmark CLiMB trial is now peer-reviewed, demonstrating HelioLiver's superior sensitivity for early-stage HCC versus ultrasound.

Read more
InterviewApril 15, 2026

Helio Genomics CEO on the Future of Early Cancer Detection

Dr. Bharat Tewarie on where the company and the field are headed.

Watch the interview
Press ReleaseMarch 28, 2026

HelioLiver Now Available Through Quest Diagnostics

Expanding access to our epigenomic blood test for liver cancer.

Read more